Sulfated polysaccharide directs therapeutic angiogenesis via endogenous VEGF secretion of macrophages

Notwithstanding the remarkable progress in the clinical treatment of ischemic disease, proangiogenic drugs mostly suffer from their abnormal angiogenesis and potential cancer risk, and currently, no off-the-shelf biomaterials can efficiently induce angiogenesis. Here, we reported that a semisynthetic sulfated chitosan (SCS) readily engaged anti-inflammatory macrophages and increased its secretion of endogenous vascular endothelial growth factor (VEGF) to induce angiogenesis in ischemia via a VEGF-VEGFR2 signaling pathway. The depletion of host macrophages abrogated VEGF secretion and vascularization in implants, and the inhibition of VEGF or VEGFR2 signaling also disrupted the macrophage-associated angiogenesis. In addition, in a macrophage-inhibited mouse model, SCS efficiently helped to recover the endogenous levels of VEGF and the number of CD31(hi)Emcn(hi) vessels in ischemia. Thus, both sulfated group and pentasaccharide sequence in SCS played an important role in directing the therapeutic angiogenesis, indicating that this highly bioactive biomaterial can be harnessed to treat ischemic disease.

Automated summary

A study found that semisynthetic sulfated chitosan (SCS) can induce angiogenesis by increasing the secretion of VEGF by macrophages, aiding in the treatment of ischemic diseases. SCS works through the VEGF-VEGFR2 signaling pathway, and inhibiting VEGF or VEGFR2 signals can affect the role of macrophages in angiogenesis.